Contemporary approaches to adult obesity treatment

Nurse Practitioner

Volumn 36, Issue 9, 2011, Pages 37-46

  Meires, Jan ^a   Christie, Catherine ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF NURSING   (United States)

^b UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

Adult obesity treatment; Pharmacotherapy for obesity; Transdisciplinary team approach to obesity management

Indexed keywords

ANTIOBESITY AGENT;

ADULT; ARTICLE; EVIDENCE BASED MEDICINE; EXERCISE; HUMAN; LOW CALORY DIET; OBESITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTI-OBESITY AGENTS; DIET, REDUCING; EVIDENCE-BASED MEDICINE; EXERCISE; HUMANS; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84855568453     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000403291.15266.d6     Document Type: Article

References (36)

1. Christie C, Meires J, Watkins J. Use your team's might to drive back obesity. Nurse Pract. 2007;32(5):31-36.
2. US Preventive Services Task Force. Screening for Obesity in Adults. Ann Intern Med. 2003;139(11):930-932.
3. McPhee SJ, Papadakis MA, Tierney LM. Current Medical Diagnosis & Treatment. New York: McGraw-Hill Medical; 2007:1267-1270.
4. Centers for Disease Control Morbidity and Mortality Weekly Report. Differences in prevalence of obesity among Black, White and Hispanic adults: United States, 2006-2008. 2009.
5. Kolasa K, Collier DN, Cable K. Weight loss strategies that really work. J Fam Pract. 2010;59(7):380-385.
6. Siegal J. Obesity. In: Buttaro TM, Trybulski J, Bailey PB, eds. Primary Care: A Collaborative Approach. 3rd ed. St. Louis: Mosby Elsevier; 2008.
7. Buse J. The science of obesity across time and ages. Medscape. 2009.
8. The NCMHD Center for Excellence for Nutritional Genomics. Information. 2010.
9. Heuther S. Alteration in digestive function. In: McCanee K, Huether S, Brashers V, eds. Pathophysiology: The Biologic Basis for Disease in Adults and Children. Maryland Heights: Mosby Elsevier; 2010:1477-1480.
10. Bloom SR, Kuhajda FP, Laher I, et al. The obesity epidemic: pharmacological challenges. Mol Interv. 2008;8(2):82-98.
11. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005;307(5717):1909-1914.
12. Loke YK, Derry S, Pritchard-Copley A. Appetite suppressants and valvular heart disease: a systematic review. BMC Clin Pharmacol. 2002;2:6.
13. Sachdev M, Miler WC, Ryan T, Jollis GJ. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J. 2002;144(6):1065-1073.
14. Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26(2):262-273.
15. Alraei RG. Herbal and dietary supplements for weight loss. Top Clin Nutr. 2010;25(2):136-150.
16. Obesity in Nurse Practitioners' Prescribing Reference. Winter 2011;17(4);2439-245.
17. U.S. Department of Health and Human Services: U.S. Food and Drug Administration. Meridia (sibutramine): Market withdrawal due to risk of serious cardiovascular events. 2010.
18. Nkansah N, Garala M, Agness C, et al. Orlistat for the prevention of cardiovascular disease in overweight or obese individuals. Cochrane Database Syst Rev. 2007;3:1-20.
19. Rucker D, Padwai R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-1199.
20. Aponte JC, Ballesteros B, Deantonio R. Fluoxetine for overweight and obesity. Cochrane Database Syst Rev. 2008;3:1-14.
21. Smith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816-1823.
22. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev. 2006;(4):CD006162.
23. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta analysis of randomized trials. Lancet. 2007;370(9600):1706-1713.
24. Chaput JP, Tremblay A. Current and novel approaches to the drug therapy of obesity. Eur J Clin Pharmacol. 2006;62(10):793-803.
25. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on body weight loss, body composition, and quality of life in obese patients: a randomized, double blind placebo controlled trial. Lancet. 2008;372(9653):1906-1913.
26. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo controlled study. Lancet. 2009;374(9701):1606-1616.
27. Rosenstock J, Hollander P, Gadde KM, et al. A randomized, double blind, placebo controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007;30(6):1480-1486.
28. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity. 2009;17(9)1736-1743.
29. ClinicalTrials.gov. A safety and efficacy study of naltrexone SR/bupropion SR in obesity. 2010.
30. American Dietetic Association Evidence Library. (2006). Adult Weight Management Evidence Analysis Project. American Dietetic Association.
31. Uwaifo G, Griffing GT. Obesity Treatment and Management. 2011
32. Weiss EC, Galuska DA, Khan LK, Serdula MK. Weight control practices among U.S. adults. 2001-2002. Am J Prev Med. 2006; 31(1): 18-24.
33. Kaiarchian MA, Levine, MD, Kiem ML, Burke LE, Soulakova JN, Marcus MD. Impact of addressing reasons for weight loss on behavioral weight-control outcome. Am J Prev Med. 2011; 40(1): 18-24.
34. The National Weight Control Registry. NWCR facts.
35. Phelan S, Wyatt HR, Hill JO, Wing RR. Are the eating and exercise habits of successful weight losers changing? Obesity. 2006;14(4):710-716.
36. American Dietetic Association Evidence Library. Adult Weight Management Evidence Analysis Project.